18F-FAPIBiotin PET/CT: Dosimetry and Biodistribution Study

Recruiting now · Early Phase 1

Conditions studied: Malignant Neoplasm

In brief

As a new dual targeting PET radiotracer, 18F-FAPI-Biotin is promising as an excellent imaging agent applicable to various cancers. In this study, we observed the safety, biodistribution and radiation dosimetry of 18F-FAPI-Biotin in patients with various types of cancer and compared them with the results of 18F-FAPI or 18F-FDG imaging to evaluate the dosimetric characteristics and diagnostic efficacy of 18F-FAPI.

Key facts

Study ID

NCT06734572

Run by

First Affiliated Hospital of Fujian Medical University

People needed

5

Starts

2024-06-25

Expected to finish

2025-12-31

Last updated by the study team

2024-12-16

Who can join

Age: 18 and older, up to 80. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Various solid tumors with available histopathological findings • Signed informed consent

You may not qualify if…

• pregnant or lactational women • who suffered from severe hepatic and renal insufficiency

Where it is running

• Department of Nuclear Medicine, First Affiliated Hospital of Fujian Medical University — Fuzhou, Fujian, China (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.